<h3>深度简报：</h3>
<ul>
<li>PsiThera，前 Roivant Sciences 的子公司，周三宣布在 A 轮融资中筹集了 4750 万美元，以帮助开发其肿瘤坏死因子靶向药物候选者的组合。</li>
<li>这家生物技术公司曾被称为 Psivant Therapeutics，正在利用其专有的人工智能平台寻找能够以口服形式提供生物药物类似疗效的新分子。</li>
<li>其早期投资者包括 Lightstone Ventures 和 Samsara BioCapital，这两家公司共同主导了此次风险投资轮，以及 Roivant、YK Bioventures 和 Eurofarma Ventures。</li>
</ul>
<h3>深度洞察：</h3>
<p>靶向 TNF 的生物药物改变了许多自身免疫疾病的治疗方式。像 Humira 和 Enbrel 这样的药物有效对抗多种疾病，每年常常赚取数十亿美元。但它们通常通过注射或输液给药，因此制造和管理更为复杂。</p>
<p>PsiThera 的目标是将这些生物药物转变为更便宜且更易服用的口服药物。该公司依靠人工智能寻找新的方法来附着并阻断 TNF，并相信可以通过预测和模拟蛋白质微小结构变化的方式，使小分子实现这一点，PsiThera 的创始人兼首席创新官 Woody Sherman 表示。</p>
<p><img src="https://imageproxy.pbkrs.com/https://imgproxy.divecdn.com/Y_CuiBWIuXP4iE2hZhny_GezgpUY5T6wYTpi5IU8gPo/g:ce/rs:fit:1600:0/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9Xb29keV9TaGVybWFuX2hlYWRzaG90XzIwMjQuanBn.webp?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://imgproxy.divecdn.com/Y_CuiBWIuXP4iE2hZhny_GezgpUY5T6wYTpi5IU8gPo/g:ce/rs:fit:1600:0/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9Xb29keV9TaGVybWFuX2hlYWRzaG90XzIwMjQuanBn.webp"/></p>
<p>Woody Sherman 是 PsiThera 的创始人兼首席创新官，曾被称为 Psivant Therapeutics。</p>
<p>获得 PsiThera 的许可</p>
<p>PsiThera 对生物药物口服形式的可能性充满热情，周一 Kymera Therapeutics 的数据发布使其股价飙升，宣布一种口服蛋白降解剂似乎安全且对炎症靶点有效。</p>
<p>“在过去 10 年中，针对这些以前难以处理的靶点的口服疗法的例子越来越多，” Sherman 说。</p>
<p>PsiThera 声称其人工智能平台可以缩短科学家寻找潜在分子到优化其用于临床前研究的时间。</p>
<p>与此同时，怀疑人工智能设计药物的人对该技术能否找到高质量药物持怀疑态度。少数进入临床测试的药物，如 Recursion Pharmaceuticals 的神经血管药物，并未显示出显著疗效。</p>
<p>Sherman 和 PsiThera 首席执行官 Eric Shaff 意识到这些顾虑。然而，他们坚持认为现在仍处于早期阶段，未来人工智能药物发现的梦想可能会变为现实。</p>
<p><img src="https://imageproxy.pbkrs.com/https://imgproxy.divecdn.com/38nzXw1XO5GpCyHQGY0GPhKJIL3NVW0u9Gby6KWU1Rw/g:ce/rs:fit:1600:0/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9FcmljX0hlYWRzaG90LnBuZw==.webp?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://imgproxy.divecdn.com/38nzXw1XO5GpCyHQGY0GPhKJIL3NVW0u9Gby6KWU1Rw/g:ce/rs:fit:1600:0/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9FcmljX0hlYWRzaG90LnBuZw==.webp"/></p>
<p>Eric Shaff 是 PsiThera 的首席执行官。</p>
<p>获得 PsiThera 的许可</p>
<p>“人工智能可能会改变游戏规则，但人类在这个过程中扮演着至关重要的角色，” Shaff 说。</p>
<p>PsiThera 于 2022 年从 Roivant 分拆出来，后者推出了 Telavant 和 Dermavant 等公司，作为其 “中心 - 辐射” 生物技术创建模型的一部分。Shaff 表示，PsiThera 围绕其药物发现引擎建立，并在确定 TNF 作为首个靶点后进行外部推出。</p>
<p>该公司计划在明年选择其主导项目候选者。</p>
<p><em>更正：该故事的早期版本错误拼写了 Eric Shaff 的姓氏，并包含了 PsiThera 分拆的错误年份。</em></p>

ROIV

<p>PsiThera 是一家从 Roivant Sciences 分拆出来的公司，在 A 轮融资中筹集了 4750 万美元，旨在开发针对肿瘤坏死因子的 AI 设计口服药物，以治疗免疫疾病。尽管对 AI 在药物发现中的有效性存在怀疑，该公司仍希望利用其 AI 平台将生物制剂转化为口服药物。PsiThera 计划在明年选择其主要项目候选药物</p>

<h3>Dive Brief:</h3>
<div class="lb-trans"><h3>深度简报：</h3>
</div><ul>
<li>PsiThera, a former Roivant Sciences subsidiary, announced Wednesday it raised $47.5 million in a Series A round to help develop its portfolio of tumor necrosis factor-targeting drug candidates.</li>
<li>Once known as Psivant Therapeutics, the biotechnology company is using its proprietary artificial intelligence platform to find new molecules that can deliver biologic-like efficacy in an oral form.</li>
<li>Its early backers include Lightstone Ventures and Samsara BioCapital, which co-led the venture capital round, as well as Roivant, YK Bioventures, and Eurofarma Ventures.</li>
</ul>
<div class="lb-trans"><ul>
<li>PsiThera，前 Roivant Sciences 的子公司，周三宣布在 A 轮融资中筹集了 4750 万美元，以帮助开发其肿瘤坏死因子靶向药物候选者的组合。</li>
<li>这家生物技术公司曾被称为 Psivant Therapeutics，正在利用其专有的人工智能平台寻找能够以口服形式提供生物药物类似疗效的新分子。</li>
<li>其早期投资者包括 Lightstone Ventures 和 Samsara BioCapital，这两家公司共同主导了此次风险投资轮，以及 Roivant、YK Bioventures 和 Eurofarma Ventures。</li>
</ul>
</div><h3>Dive Insight:</h3>
<div class="lb-trans"><h3>深度洞察：</h3>
</div><p>Biologic medicines that target TNF, a protein involved in inflammation, changed the way many autoimmune conditions are treated. Drugs like Humira and Enbrel effectively combat a wide range of diseases and regularly earned billions of dollars annually. But they're also given via injections or infusions, and thus are more complicated to make and administer.</p>
<div class="lb-trans"><p>靶向 TNF 的生物药物改变了许多自身免疫疾病的治疗方式。像 Humira 和 Enbrel 这样的药物有效对抗多种疾病，每年常常赚取数十亿美元。但它们通常通过注射或输液给药，因此制造和管理更为复杂。</p>
</div><p>PsiThera’s ambitions are to take those biologics and turn them into oral medications that are cheaper to produce and easier to take. The company is leaning on AI to find new ways to latch onto and block TNF, and believes it can make small molecules do so by predicting and simulating the minuscule ways that a protein changes its structure, also known as protein motion, said Woody Sherman, PsiThera’s founder and chief innovation officer.</p>
<div class="lb-trans"><p>PsiThera 的目标是将这些生物药物转变为更便宜且更易服用的口服药物。该公司依靠人工智能寻找新的方法来附着并阻断 TNF，并相信可以通过预测和模拟蛋白质微小结构变化的方式，使小分子实现这一点，PsiThera 的创始人兼首席创新官 Woody Sherman 表示。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://imgproxy.divecdn.com/Y_CuiBWIuXP4iE2hZhny_GezgpUY5T6wYTpi5IU8gPo/g:ce/rs:fit:1600:0/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9Xb29keV9TaGVybWFuX2hlYWRzaG90XzIwMjQuanBn.webp" alt="" original-src="https://imgproxy.divecdn.com/Y_CuiBWIuXP4iE2hZhny_GezgpUY5T6wYTpi5IU8gPo/g:ce/rs:fit:1600:0/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9Xb29keV9TaGVybWFuX2hlYWRzaG90XzIwMjQuanBn.webp"/></p>
<p>Woody Sherman is the founder and chief innovation officer of PsiThera, formerly known as Psivant Therapeutics.</p>
<div class="lb-trans"><p>Woody Sherman 是 PsiThera 的创始人兼首席创新官，曾被称为 Psivant Therapeutics。</p>
</div><p>Permission granted by PsiThera</p>
<div class="lb-trans"><p>获得 PsiThera 的许可</p>
</div><p>Adding to PsiThera’s enthusiasm for what’s possible for a biologic in a pill was Monday’s data readout from Kymera Therapeutics, whose shares skyrocketed on the announcement that an oral protein degrader appeared safe and worked on an inflammation target.</p>
<div class="lb-trans"><p>PsiThera 对生物药物口服形式的可能性充满热情，周一 Kymera Therapeutics 的数据发布使其股价飙升，宣布一种口服蛋白降解剂似乎安全且对炎症靶点有效。</p>
</div><p>“There's been a growing number of examples over the course of the past 10 years of oral therapies for these previously intractable targets,” Sherman said.</p>
<div class="lb-trans"><p>“在过去 10 年中，针对这些以前难以处理的靶点的口服疗法的例子越来越多，” Sherman 说。</p>
</div><p>PsiThera claims its AI platform can shrink the time scientists spend finding a potential molecule to optimizing it for preclinical studies.</p>
<div class="lb-trans"><p>PsiThera 声称其人工智能平台可以缩短科学家寻找潜在分子到优化其用于临床前研究的时间。</p>
</div><p>Skeptics of AI-designed drugs, meanwhile, have been unconvinced that the technology can find high-quality medicines. The few that have made it to clinical testing, such as Recursion Pharmaceuticals’ neurovascular drug, have not demonstrated meaningful efficacy.</p>
<div class="lb-trans"><p>与此同时，怀疑人工智能设计药物的人对该技术能否找到高质量药物持怀疑态度。少数进入临床测试的药物，如 Recursion Pharmaceuticals 的神经血管药物，并未显示出显著疗效。</p>
</div><p>Sherman and PsiThera CEO Eric Shaff are aware of these reservations. Yet they maintain it’s still early days and that down the line, what may seem like a pipe dream for the future of AI drug discovery could become reality.</p>
<div class="lb-trans"><p>Sherman 和 PsiThera 首席执行官 Eric Shaff 意识到这些顾虑。然而，他们坚持认为现在仍处于早期阶段，未来人工智能药物发现的梦想可能会变为现实。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://imgproxy.divecdn.com/38nzXw1XO5GpCyHQGY0GPhKJIL3NVW0u9Gby6KWU1Rw/g:ce/rs:fit:1600:0/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9FcmljX0hlYWRzaG90LnBuZw==.webp" alt="" original-src="https://imgproxy.divecdn.com/38nzXw1XO5GpCyHQGY0GPhKJIL3NVW0u9Gby6KWU1Rw/g:ce/rs:fit:1600:0/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9FcmljX0hlYWRzaG90LnBuZw==.webp"/></p>
<p>Eric Shaff is the CEO of PsiThera</p>
<div class="lb-trans"><p>Eric Shaff 是 PsiThera 的首席执行官。</p>
</div><p>Permission granted by PsiThera</p>
<div class="lb-trans"><p>获得 PsiThera 的许可</p>
</div><p>“AI may change the game, but humans have an essential role in the process,” Shaff said.</p>
<div class="lb-trans"><p>“人工智能可能会改变游戏规则，但人类在这个过程中扮演着至关重要的角色，” Shaff 说。</p>
</div><p>PsiThera broke off in 2022 from Roivant, which launched companies like Telavant and Dermavant as part of its “hub-and-spoke” biotech creation model. PsiThera was built around its drug discovery engine, Shaff said, and launched externally once it identified TNF as its first target.</p>
<div class="lb-trans"><p>PsiThera 于 2022 年从 Roivant 分拆出来，后者推出了 Telavant 和 Dermavant 等公司，作为其 “中心 - 辐射” 生物技术创建模型的一部分。Shaff 表示，PsiThera 围绕其药物发现引擎建立，并在确定 TNF 作为首个靶点后进行外部推出。</p>
</div><p>The company plans to select its lead program candidate next year.</p>
<div class="lb-trans"><p>该公司计划在明年选择其主导项目候选者。</p>
</div><p><em>Correction: A previous version of this story misspelled Eric Shaff's last name, and included the incorrect year for PsiThera's spinout.</em></p>
<div class="lb-trans"><p><em>更正：该故事的早期版本错误拼写了 Eric Shaff 的姓氏，并包含了 PsiThera 分拆的错误年份。</em></p>
</div>

Roivant 的一家分拆公司正在押注于由人工智能设计的免疫疾病药物